Natália Araújo has a PharmD (six-year curriculum program, Faculty of Pharmacy, University of Porto, 2001), and she was a research fellow at the Institute of Molecular Biology of the University of Porto. She worked as a community pharmacist at Porto for ten years. She decided to begin a carrer in Public Health research in 2014. She was a research fellow of the project NEON-BC: A five-year prospective cohort study on the neurological complications of breast cancer: frequency and impact in patient-reported outcomes (POCI-01-0145-FEDER-016867), and she was awarded a grant from the Foundation for Science and Technology (SFRH/BD/119390/2016) to carry out her Ph.D. thesis Longitudinal assessment of cognitive decline in breast and prostate cancer survivors, which she completed in 2021.
She is currently a co-supervisor of one Master’s dissertation and she is an integrated research member of the Laboratory for Integrative and Translational Research in Population Health (ITR; lab. LT4 ‘Patient and Population Outcomes Research: towards a precision approach to medicine and public health) .
Healthcare (Basel), 2022 Mar 31;10(4):661. doi: 10.3390/healthcare10040661.
, 2022 Mar 21;29(3):2141-2153. doi: 10.3390/curroncol29030173.
Cancer Causes Control, 2022 Mar 19. doi: 10.1007/s10552-022-01565-y. Online ahead of print.
Helicobacter, https://pubmed.ncbi.nlm.nih.gov/35235224/
Cancer Epidemiol Biomarkers Prev, 2022 Jan;31(1):200-209. doi: 10.1158/1055-9965.EPI-21-0402. Epub 2021 Nov 2.
BMJ Open, 2021 Feb 15;11(2):e043844. doi: 10.1136/bmjopen-2020-043844.
J Public Health (Oxf), 2020 Aug 5:fdaa118. doi: 10.1093/pubmed/fdaa118. Online ahead of print.
Am J Alzheimers Dis Other Demen, 2019 Feb;34(1):49-56. doi: 10.1177/1533317518813550. Epub 2018 Dec 4.